Olema Pharmaceuticals
Price & Volume
Stats
See more52W Range | $2.86-$16.62 |
Market Cap | $302M |
Shares Short | 6M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.28 |
News
See moreYahoo Finance • last year
15 Small-Cap Stocks with High Potential
Yahoo Finance • last year
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
Yahoo Finance • last year
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
Yahoo Finance • 2 years ago
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
About
CEO | Dr. Sean P. Bohen M.D., Ph.D. |
Address | 780 Brannan Street, San Francisco, CA, United States, 94103 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 96 |
